Keros Therapeutics, Inc.
KROS
$9.93
-$0.14-1.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -4.68% | -97.30% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -4.68% | -97.30% | |||
| Cost of Revenue | -9.63% | -8.75% | |||
| Gross Profit | 9.74% | -231.50% | |||
| SG&A Expenses | -13.59% | 15.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.20% | -0.31% | |||
| Operating Income | 11.29% | -89.61% | |||
| Income Before Tax | 5.07% | -186.94% | |||
| Income Tax Expenses | -- | -6.32% | |||
| Earnings from Continuing Operations | -1.05% | -222.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.05% | -222.27% | |||
| EBIT | 11.29% | -89.61% | |||
| EBITDA | 11.46% | -91.94% | |||
| EPS Basic | -40.01% | -381.36% | |||
| Normalized Basic EPS | -32.05% | -326.89% | |||
| EPS Diluted | -40.27% | -379.22% | |||
| Normalized Diluted EPS | -32.05% | -326.89% | |||
| Average Basic Shares Outstanding | -27.83% | -33.05% | |||
| Average Diluted Shares Outstanding | -27.83% | -33.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||